A Randomized, Double-Blind, Placebo-Controlled Study to Test the Anti-Inflammatory Properties of RPL554 in Healthy Subjects
Latest Information Update: 21 Oct 2013
At a glance
- Drugs Ensifentrine (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Verona Pharma
Most Recent Events
- 09 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 09 Sep 2013 Status changed from recruiting to completed.
- 10 Jul 2012 New trial record